Catalysts for $ONC
18 tracked
Nov 5, 2026
earnings
BeOne Medicines Ltd. earnings
BeOne Medicines Ltd.
→
Aug 5, 2026
earnings
BeOne Medicines Ltd. earnings
BeOne Medicines Ltd.
→
May 6, 2026
earnings
BeOne Medicines Ltd. earnings
BeOne Medicines Ltd.
→
Apr 30, 2026
phase 1 initiation
BeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)
BGC-0979
→
Apr 30, 2026
phase 1 completion
BeOne Medicines AG — BG-89894 (Phase I Trial Completion)
BG-89894
→
Dec 9, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Dec 9, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Dec 9, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Dec 2, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
May 1, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Apr 22, 2025
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
Mar 13, 2024
approval
TEVIMBRA (TISLELIZUMAB-JSGR) — FDA approval
BeOne Medicines Ltd.
→
COMPLETED
phase readout
NCT04602598: Zanubrutinib in Patients With IgG4-Related Disease
BeOne Medicines Ltd.
→